Zenith Capital Corp. is developing various novel combinations of BET inhibitors with other targeted agents for numerous oncology indications in pre-selected or enriched patient populations. Company lead compound, ZEN-3694 is undergoing clinical development in multiple clinical trials: Phase 2b metastatic castration resistant prostate (mCRPC) cancer trialin combination with androgen receptor inhibitor, XTANDI (enzalutamide): Randomized trial comparing XTANDI in combination with ZEN-3694 to XTANDI treatment alone in patients with mCRPC.

Conducted in collaboration Astellas Pharma and Newsoara Biopharma. This study is active and currently recruiting across multiple sites in the US and is in the activation stage in China. Differentiated study that will focus on addressing a significant unmet need in patients with AR independent tumors.

Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib): Conducted in collaboration with Pfizer and Newsoara Biopharma. This study is an expansion of the ongoing Phase 2 trial and is in the activation stage in US/EU/China. Based on discussions with US FDA, this Phase 2b trial – with a positive outcome – can potentially enable registration of ZEN-3694 via accelerated approval.

Phase 1b/2 androgen receptor independent mCRPC trial in combination with immune checkpoint inhibitor KEYTRUDA (pembrolizumab) and XTANDI: Conducted in collaboration with Merck, the University of California, San Francisco, and the University of Michigan. Data to date shows that the combination can be dosed safely and is clinically active. The trial has progressed to the efficacy stage and is accruing well.

Phase 1b/2 ovarian cancer trial in combination with immune-checkpoint inhibitors, nivolumab and ipilimumab: National Cancer Institute is conducting this trial in collaboration with Zenith and BMS. This is a second trial combining immune-checkpoint inhibitors with ZEN-3694. Expected to enroll first patient in the first quarter of 2022. Phase 1b/2 solid tumors and lymphoma trial in combination with entinostat: National Cancer Institute is conducting this trial in collaboration with Zenith and SyndaxExpected to enroll first patient in the first half of 2022.